HOLLISTON, Mass., July 18, 2017 -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will announce results for its second quarter 2017 after market trading hours on Thursday, July 27, 2017. A conference call to discuss the company's second quarter 2017 financial results and its operations is scheduled for that same date at 4:30 PM ET. On that call, management may respond to questions from the audience and provide information on any of a number of topics related to the business, including operations, plans and outlook.
Participating in the call will be Jeffrey A. Duchemin, President and Chief Executive Officer; and Robert Gagnon, Chief Financial Officer of Harvard Bioscience. Investors can access the live conference call by dialing the following phone numbers: toll-free 1-800-708-4539, or international: 1-847-619-6396, and referencing the conference ID# 45318167.
The conference will be simultaneously webcast and can be accessed through the Harvard Bioscience website. To listen to the webcast, log on to the webcast at:
http://investor.harvardbioscience.com/
and click on the Earnings Call icon. Financial information presented on the call, including the earnings release, will also be available on the investor relations section of the website.
If you are unable to listen to the live conference call, the webcast will be available on the Company's website through August 3, 2017.
To add this meeting to your calendar visit: http://investor.harvardbioscience.com/ and click “remind me”.
About Harvard Bioscience
Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of solutions to advance life science. Our products are sold to thousands of researchers in over 100 countries through our global sales organization, websites, catalogs, and through distributors including Thermo Fisher Scientific Inc., VWR, and other specialized distributors. We have sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France, Canada and China. For more information, please visit our website at www.harvardbioscience.com.
CONTACTS: Corey Manchester Director, Finance and Investor Relations Tel: 508 893 8999


Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 



